ProfileGDS5678 / 1452235_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 55% 59% 54% 56% 57% 56% 54% 57% 54% 61% 57% 57% 56% 57% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.4391355
GSM967853U87-EV human glioblastoma xenograft - Control 23.5621159
GSM967854U87-EV human glioblastoma xenograft - Control 33.347154
GSM967855U87-EV human glioblastoma xenograft - Control 43.3588356
GSM967856U87-EV human glioblastoma xenograft - Control 53.4106557
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.5224956
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.429354
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.4337457
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.3112154
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.6101161
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.4587157
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.4120357
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.4394256
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.4325657